Hematology
Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.
Recent Discussions
How do you approach the use of teclistamab plus daratumumab in patients with relapsed/refractory multiple myeloma who have previously been exposed to daratumumab or isatuximab?
The treatment of patients at first relapse has changed dramatically over the last few years - first with the option of Carvykti (cilta-cel) for fit patients, and now the option of teclistamab-based regimens. At first we were only able to use teclistamab + daratamumab as a result of MajesTEC-3, and m...
Would you recommend oral or intravenous iron in a chronic kidney disease stage 4 patient who is not on an ESA and has a hemoglobin of 12.7 g/dl and an iron saturation of less than 20%?
I would not necessarily treat this patient with iron at all. I would check serum ferritin. If low would do a colonoscopy or look for causes of iron deficiency. If not low would observe. In general though for patients with CKD (not on dialysis yet) who need iron therapy, I would try oral iron first. ...
How do you approach treatment of aceruloplasminemia with biallelic CP mutations and brain iron deposition?
These are difficult. If the hemoglobin is high enough, you can try phlebotomy, but anemia will often restrict this. Chelation is the only other treatment. The neurological decline is often relentless despite these efforts.
How would you manage severe Factor XII deficiency in a patient with recurrent pregnancy loss?
A causal relationship between factor XII deficiency and thrombophilia or recurrent pregnancy loss has not been firmly established. Although some studies have shown low factor XII levels in a relatively high proportion of individuals with recurrent pregnancy loss, it is not possible to exclude ascert...
How do you approach management autoimmune lymphoproliferative syndrome (ALPS) complicated by HLH?
Excellent and tough question. There are no direct guidelines for this specific question. We will have to extrapolate from other evidence and clinical reasoning.Investigation of the trigger must occur in parallel with management. I will discuss how I approach investigation first and then management.I...
Would you consider long term avatrombopag use in patients with cirrhosis requiring higher platelet counts for medical therapy?
In general, no, I would not use long-term avatrombopag in patients with cirrhosis requiring higher platelet counts for medical therapy due to the perceived thrombotic risk and hemostatic abnormalities of patients with liver disease.One thing to note in assessing the risk of long-term TPO mimetic the...
Do you offer IV iron first line to women with iron deficiency anemia from heavy menstrual bleeding?
I offer first-line IV iron because oral iron cannot keep up with the losses from heavy menstrual bleeding, and the majority can't tolerate it. I routinely give a gram of LMW iron dextran in one hour, Feraheme (not ferumoxytol generic) 1,020 mg in 30 minutes, or ferric derisomaltose 1 gram in 30 minu...
How would you approach mantle cell lymphoma in very elderly patients?
For patients who are very elderly, my approach depends on the patient's performance status, other comorbidities, disease features/disease behavior, and indications for treatment. There are patients with MCL who can be observed at diagnosis (those with leukemic non-nodal disease but also those with l...
How do you approach making an acute pain IV opioid plan for a new adult SCD patient who doesn’t remember what has worked for them in the past?
I create an FYI at the initial clinic visit and go over the FYI with them so that we are both comfortable with the plan and the patient knows their plan. The first thing I would do is look through outside records, for example, if they are available in Care Everywhere. If that is not available, then ...
Would you continue or stop anticoagulation for a DVT/PE in a patient with active cancer who has completed 6 months of therapy?
This is an important question that we didn’t really have a clear answer for… until this year when an NEJM RCT was published! Mahé et al., PMID 40162636 In this RCT, patients with cancer-associated VTE who completed 6 months of full-dose apixaban were randomized to half-dose apixaban vs. full-dos...